Gilder Gagnon Howe & Co’s Thermo Fisher Scientific TMO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,929	Closed	-$5.03M	–	272
2023 Q3	$5.03M	Buy	9,929 +147	+2%	+$78.3K	0.08%	141
2023 Q2	$5.1M	Buy	+9,782	New	+$5.28M	0.07%	154

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Gilder Gagnon Howe & Co's TMO Position: Q4 2023 in Review

Gilder Gagnon Howe & Co sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 9,929 shares — an estimated $5.03M sold.

Gilder Gagnon Howe & Co first reported a position in TMO in Q2 2023 and held it in 2 quarters. The position peaked at $5.1M in Q2 2023. 2,488 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

Gilder Gagnon Howe & Co reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 9,929 Thermo Fisher Scientific shares in Q4 2023, an estimated $5.03M.
Gilder Gagnon Howe & Co first reported a position in Thermo Fisher Scientific in Q2 2023 and held it in 2 quarters.
Gilder Gagnon Howe & Co's Thermo Fisher Scientific position peaked at $5.1M in Q2 2023.
2,488 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2023, filed 14 Feb 2024.